Results 221 to 230 of about 54,010 (241)

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

Lancet, The, 1998
Philippe Rougier, Emilio Bajetta, Norbert Niederle   +2 more
exaly  

Importance of UDP-glucuronosyltransferase 1A1∗6 for irinotecan toxicities in Japanese cancer patients

Cancer Letters, 2008
Kimie Sai, Yoshiro Saito, Kuniaki Shirao   +2 more
exaly  

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

Annals of Oncology, 2004
C Peschel, Johannes Bukki, V Gorbunova   +2 more
exaly  

Irinotecan

Reactions Weekly, 1999
openaire   +1 more source

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

Annals of Oncology, 2013
S R Park, David Cunningham, Y K Kang
exaly  

Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats

European Journal of Pharmaceutical Sciences, 2009
Manu Jaggi, Sushama Talegaonkar
exaly  

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma

Annals of Oncology, 2003
E Raymond, M Fabbro, V Boige
exaly  

Irinotecan

Reactions Weekly, 1993
openaire   +1 more source

ST. JOHN'S WORT INTERFERES WITH IRINOTECAN

Ca-A Cancer Journal for Clinicians, 2002
exaly  

Irinotecan and its active metabolite, SN‐38: review of bioanalytical methods and recent update from clinical pharmacology perspectives

Biomedical Chromatography, 2010
Nuggehally R Srinivas
exaly